Access to Medicines – Page 26

HIV/AIDS Treatment, Microbicide and Vaccine Advocates Release Plan of Action and Joint Statement of Commitment

September 25, 2022July 14, 2004

Controlling Drug Costs for People Living with HIV/AIDS: Federal Regulation of Pharmaceutical Prices in Canada

October 4, 2022May 11, 2004

The paper: highlights the significance of policy on pharmaceutical pricing, given increasing costs and spending on medicines as part of overall healthcare spending in Canada; identifies recent developments that are important because they inform current debates in Canada over regulating drug prices, or our policies in general relating to pharmaceuticals; outlines current federal law and … Read more

WTO Patent Rules, Canada’s Bill C-9, and Civil Society Treatment Activism – Poster at the 13th Annual Canadian Conference on HIV/AIDS Research

September 25, 2022May 10, 2004

Canada Proceeds with Bill C-9 on Cheaper Medicine Exports: NGOs say initiative is important, and urge other countries to avoid the flaws in the Canadian model

September 25, 2022April 28, 2004

Latest Amendments to Canada Patent Act a Good Start, But Still Need Work

September 25, 2022April 20, 2004

Submission to the Standing Committee on Industry, Science and Technology on Proposed Government Amendments to Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act

September 25, 2022April 19, 2004

Statement on Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act

September 25, 2022April 2, 2004

HIV/AIDS and Pharmaceutical Pricing

September 25, 2022March 31, 2004

This info sheet is one in a series of seven info sheets on the federal regulation of pharmaceutical prices in Canada. Health Spending and the Pharmaceutical Industry Controlling Medicine Prices: Evolution of Canadian Law Patented Medicine Prices Review Board Preventing Excessive Pricing of Patented Medicines Jurisdiction of the PMPRB Pricing of HIV/AIDS Drugs Trends in … Read more

Letter to the Standing Committee on Industry, Science and Technology re: Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act

September 25, 2022March 26, 2004

“I write to follow up on our previous submissions to the Standing Committee regarding Bill C-9, Canada’s laudable initiative to implement the WTO General Council Decision of August 30, 2003 to enable countries lacking sufficient pharmaceutical manufacturing capacity to ‘make effective use’ of compulsory licensing to obtain lower cost generic pharmaceutical products manufactured in Canada…”

Letter to the Standing Committee on Industry, Science and Technology re: Bill C-9 and the issue of NGO procurement of Canadian-made phramaceuticals

September 25, 2022March 23, 2004

“As was requested by the Committee when we appeared before you on February 26, 2004, we have provided the Committee with our supplementary submissions regarding the alternatives to the ‘right of refusal’ that had been proposed to the Committee… “However, discussions at subsequent Committee meetings have indicated that Committee members are under a fundamental misapprehension … Read more